Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma

Mouhoubi, Nesrine; Bamba‐Funck, Jessica; Sutton, A.; Blaise, Lorraine; Séror, Olivier; Ganne‐Carrié, Nathalie; Ziol, Marianne; N’Kontchou, Gisèle; Charnaux, Nathalie; Nahon, Pierre; Nault, Jean‐Charles; Guyot, Erwan

doi:10.2147/jhc.s382226

Cited by 2 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that GPC3 expression levels in HCC tissues are associated with tumor aggressiveness and poor prognosis, including tumor size, vascular invasion, and metastasis ( 36 , 37 ). Elevated serum levels of GPC3 have also been associated with worse overall survival and disease-free survival in patients with HCC ( 38 ). Based on these data, GPC3 may be useful for stratifying HCC patients based on their prognosis and guiding treatment decisions.…”

Section: Hcc Biomarkers: From Disease Surveillance To Therapeutic Tar...mentioning

confidence: 99%

Immunotherapy, targeted therapy, and their cross talks in hepatocellular carcinoma

Liu,

Park,

Shen

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a challenging malignancy with limited treatment options beyond surgery and chemotherapy. Recent advancements in targeted therapies and immunotherapy, including PD-1 and PD-L1 monoclonal antibodies, have shown promise, but their efficacy has not met expectations. Biomarker testing and personalized medicine based on genetic mutations and other biomarkers represent the future direction for HCC treatment. To address these challenges and opportunities, this comprehensive review discusses the progress made in targeted therapies and immunotherapies for HCC, focusing on dissecting the rationales, opportunities, and challenges for combining these modalities. The liver’s unique physiology and the presence of fibrosis in many HCC patients pose additional challenges to drug delivery and efficacy. Ongoing efforts in biomarker development and combination therapy design, especially in the context of immunotherapies, hold promise for improving outcomes in advanced HCC. Through exploring the advancements in biomarkers and targeted therapies, this review provides insights into the challenges and opportunities in the field and proposes strategies for rational combination therapy design.

show abstract

Section: Hcc Biomarkers: From Disease Surveillance To Therapeutic Tar...mentioning

confidence: 99%

Immunotherapy, targeted therapy, and their cross talks in hepatocellular carcinoma

Liu,

Park,

Shen

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Soluble Proteoglycans and Proteoglycan Fragments as Biomarkers of Pathological Extracellular Matrix Remodeling

Kemberi,

Minns,

Santamaria

2024

Proteoglycan Research

View full text Add to dashboard Cite

Proteoglycans and their proteolytic fragments diffuse into biological fluids such as plasma, serum, urine, or synovial fluid, where they can be detected by antibodies or mass‐spectrometry. Neopeptides generated by the proteolysis of proteoglycans are recognized by specific neoepitope antibodies and can act as a proxy for the activity of certain proteases. Proteoglycan and proteoglycan fragments can be potentially used as prognostic, diagnostic, or theragnostic biomarkers for several diseases characterized by dysregulated extracellular matrix remodeling such as osteoarthritis, rheumatoid arthritis, atherosclerosis, thoracic aortic aneurysms, central nervous system disorders, viral infections, and cancer. Here, we review the main mechanisms accounting for the presence of soluble proteoglycans and their fragments in biological fluids, their potential application as diagnostic, prognostic, or theragnostic biomarkers, and highlight challenges and opportunities ahead of their clinical translation.

show abstract

Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma

Cited by 2 publications

References 57 publications

Immunotherapy, targeted therapy, and their cross talks in hepatocellular carcinoma

Immunotherapy, targeted therapy, and their cross talks in hepatocellular carcinoma

Soluble Proteoglycans and Proteoglycan Fragments as Biomarkers of Pathological Extracellular Matrix Remodeling

Contact Info

Product

Resources

About